Trial · NCT02904265
Efficacy Study of Acetazolamide Versus Diazepam in Continuous Spike and Wave/Landau-Kleffner Syndrome
NCT02904265, Phase 2, Phase 3, Terminated, Mayo Clinic; results first posted 2020-06-11
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy Study of Acetazolamide Versus Diazepam in Continuous Spike and Wave/Landau-Kleffner Syndrome. Trials, record NCT02904265. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02904265
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy Study of Acetazolamide Versus Diazepam in Continuous Spike and Wave/Landau-Kleffner Syndrome
- NCT number
- NCT02904265
- Status
- Terminated
- Phases
- Phase 2, Phase 3
- Enrollment
- 3 participants, actual
- Lead sponsor
- Mayo Clinic
- Conditions
- Landau-Kleffner Syndrome, Status Epilepticus, Electrographic
- Interventions
- Diazepam, Acetazolamide
- First posted
- 2016-09-16
- Last updated
- 2020-06-11
- Results first posted
- 2020-06-11
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Short-term Tolerability of Acetazolamide vs Diazepam | 4-8 weeks of start of medications | Expect improved side effect profile of acetazolamide compared to diazepam at short-term follow up |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Short-term Tolerability of Acetazolamide vs Diazepam | 4-8 weeks of start of medications | Study closed due to only 3 participants recruited | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Short-term Tolerability of Acetazolamide vs Diazepam | Diazepam | 1 | Participants | ||
| Short-term Tolerability of Acetazolamide vs Diazepam | Acetazolamide | 2 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Diazepam | 1 | |
| Overall Study | STARTED | Acetazolamide | 2 | |
| Overall Study | COMPLETED | Diazepam | 0 | |
| Overall Study | COMPLETED | Acetazolamide | 0 | |
| Overall Study | NOT COMPLETED | Diazepam | 1 | |
| Overall Study | NOT COMPLETED | Acetazolamide | 2 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Diazepam | 0 | 1 |
| Total, all-cause mortality | Acetazolamide | 0 | 2 |
| Total, other adverse events | Diazepam | 0 | 1 |
| Total, other adverse events | Acetazolamide | 0 | 2 |
| Total, serious adverse events | Diazepam | 0 | 1 |
| Total, serious adverse events | Acetazolamide | 0 | 2 |
Source ClinicalTrials.gov
Papers6
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons3
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Diazepam vs Acetazolamide: Short-term Tolerability of Acetazolamide vs Diazepam | Trial comparisons |
| Diazepam vs Acetazolamide: deaths from any cause | Trial comparisons |
| Diazepam vs Acetazolamide: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02904265
GET https://conductscience.org/api/trials/v1/NCT02904265/registered